Biodegradable polymers for delivery of therapeutic agents
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9657094-B2
Publication Date
2017-05-23
Expiration Date
Abstract
Methods, processes, systems, and compositions for treating disease are disclosed. In some cases, the present disclosure provides for delivery of therapeutic agents, in an active form, to a localized area, over an extended period of time. In one embodiment, the disclosed composition may comprise a therapeutic agent and a biodegradable polymer and/or a biodegradable polymer microsphere.
Core Innovation
The invention provides a composition for delivery of a therapeutic agent that comprises an antibody and a biodegradable hydrogel comprising alginate and chitosan, with an alginate:chitosan ratio of from about 70:30 to about 50:50. The delivery system is designed for localized and sustained delivery of therapeutic antibodies to hard-to-access central nervous system tumor sites.
The composition further includes an injectable antibody-laden hydrogel and polymer microsphere system placed into a resection cavity. The biodegradable hydrogel and biodegradable polymer microspheres mediate controlled release through diffusion and polymer degradation while protecting antibody bioactivity.
The disclosed systems include biodegradable polymer microspheres, including microspheres made of PLGA or chitosan, incorporated within the alginate and chitosan hydrogel to form a microsphere-hydrogel system. The antibody is delivered in association with the microspheres, including at least partially contained within the microsphere and/or attached to the microsphere, with the microsphere at least partially contained within the hydrogel.
Claims Coverage
The partial content provides two independent claims. The claims cover antibody delivery using biodegradable alginate/chitosan hydrogels with a defined alginate:chitosan ratio range, and a broader embodiment including biodegradable polymer microspheres embedded within the hydrogel.
Antibody therapeutic agent in biodegradable alginate-chitosan hydrogel
A therapeutic agent comprising an antibody and a biodegradable hydrogel comprising alginate and chitosan, wherein the ratio of alginate:chitosan is from about 70:30 to about 50:50.
Antibody-containing biodegradable polymer microspheres in alginate-chitosan hydrogel
A therapeutic agent comprising an antibody, a biodegradable polymer microsphere wherein the therapeutic agent is at least partially contained within the microsphere and/or attached to the microsphere, and a hydrogel comprising alginate and chitosan at a ratio of about 70:30 to about 50:50, wherein the microsphere is at least partially contained within the hydrogel.
Across the independent claims, the core claim coverage is for antibody delivery using biodegradable alginate/chitosan hydrogels with a defined alginate:chitosan ratio range, and, in the broader independent claim, biodegradable polymer microspheres that contain and/or attach the antibody and are embedded within the hydrogel.
Stated Advantages
Localized and sustained delivery of therapeutic antibodies to hard-to-access central nervous system tumor sites.
Controlled release mediated by diffusion and biodegradation of the biodegradable polymer system.
Protection of antibody bioactivity.
Overcomes blood-brain barrier limitations and rapid antibody clearance through localized delivery into a resection cavity.
Documented Applications
Delivery of anti-VEGF therapeutic antibody (e.g., bevacizumab) to glioblastoma/glioma sites using an injectable biodegradable hydrogel/microsphere system placed into a resection cavity.
Interested in licensing this patent?